Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
Williams KH, Viera de Ribeiro AJ, Prakoso E, Veillard AS, Shackel NA, Bu Y, Brooks B, Cavanagh E, Raleigh J, McLennan SV, McCaughan GW, Bachovchin WW, Keane FM, Zekry A, Twigg SM, Gorrell MD.
Williams KH, et al. Among authors: veillard as.
Diabetes Res Clin Pract. 2015 Jun;108(3):466-72. doi: 10.1016/j.diabres.2015.02.024. Epub 2015 Mar 11.
Diabetes Res Clin Pract. 2015.
PMID: 25836944